Back to Search Start Over

Ritterostatin G N 1 N , a Cephalostatin-Ritterazine Bis-steroidal Pyrazine Hybrid, Selectively Targets GRP78.

Authors :
Ambrose AJ
Santos EA
Jimenez PC
Rocha DD
Wilke DV
Beuzer P
Axelrod J
Kumar Kanduluru A
Fuchs PL
Cang H
Costa-Lotufo LV
Chapman E
La Clair JJ
Source :
Chembiochem : a European journal of chemical biology [Chembiochem] 2017 Mar 16; Vol. 18 (6), pp. 506-510. Date of Electronic Publication: 2017 Feb 02.
Publication Year :
2017

Abstract

Natural products discovered by using agnostic approaches, unlike rationally designed leads or those obtained through high-throughput screening, offer the ability to reveal new biological pathways and, hence, serve as an important vehicle to unveil new avenues in drug discovery. The ritterazine-cephalostatin family of natural products displays robust and potent antitumor activities, with sub-nanomolar growth inhibition against multiple cell lines and potent activity in xenograft models. Herein, we used comparative cellular and molecular biological methods to uncover the ritterazine-cephalostatin cytotoxic mode of action (MOA) in human tumor cells. Our findings indicated that, whereas ritterostatin G <subscript>N</subscript> 1 <subscript>N</subscript> , a cephalostatin-ritterazine hybrid, binds to multiple HSP70s, its cellular trafficking confines activity to the endoplasmic reticulum (ER)-based HSP70 isoform, GRP78. This targeting results in activation of the unfolding protein response (UPR) and subsequent apoptotic cell death.<br /> (© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.)

Details

Language :
English
ISSN :
1439-7633
Volume :
18
Issue :
6
Database :
MEDLINE
Journal :
Chembiochem : a European journal of chemical biology
Publication Type :
Academic Journal
Accession number :
28074539
Full Text :
https://doi.org/10.1002/cbic.201600669